Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of the Effect of Etanercept in Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Presence of end stage renal disease~Exclusion Criteria:~* History of Tuberculosis History of Recurrent Infection Recent AMI, Cancer within previous 5 years Presence of Hepatitis B, Hepatitis C, HIV, systemic lupus erythematosis, presence of transcutaneous access (external catheter)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Etanercept 25 mg (Type: ACTIVE_COMPARATOR): Etanercept 25 mg injection twice a week
- Saline (Type: PLACEBO_COMPARATOR): Saline injection twice a week

Based on this trial design, predict the completion outcome and termination type (if applicable).